Synaptogenix Inc SNPX:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 4:00 PM EDT
4.85quote price arrow up+0.14 (+2.97%)
Volume
36,670
52 week range
3.53 - 47.00
Loading...
  • Open4.86
  • Day High5.00
  • Day Low4.70
  • Prev Close4.71
  • 52 Week High47.00
  • 52 Week High Date07/13/23
  • 52 Week Low3.53
  • 52 Week Low Date02/13/24

Key Stats

  • Market Cap5.264M
  • Shares Out1.09M
  • 10 Day Average Volume0.07M
  • Dividend-
  • Dividend Yield-
  • Beta1.49
  • YTD % Change-27.77

KEY STATS

  • Open4.86
  • Day High5.00
  • Day Low4.70
  • Prev Close4.71
  • 52 Week High47.00
  • 52 Week High Date07/13/23
  • 52 Week Low3.53
  • 52 Week Low Date02/13/24
  • Market Cap5.264M
  • Shares Out1.09M
  • 10 Day Average Volume0.07M
  • Dividend-
  • Dividend Yield-
  • Beta1.49
  • YTD % Change-27.77

RATIOS/PROFITABILITY

  • EPS (TTM)-43.47
  • P/E (TTM)-0.11
  • Fwd P/E (NTM)-2.94
  • EBITDA (TTM)-8.308M
  • ROE (TTM)-48.31%
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date08/10/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Synaptogenix Inc

 

Content From Our Affiliates

Profile

MORE
Synaptogenix, Inc. is a clinical-stage biopharmaceutical company developing therapeutics for neurodegenerative disorders. The Company is principally focused on developing a product platform based upon a drug candidate called Bryostatin-1, which is synthesized from a natural product (bryostatin) that is isolated from a marine invertebrate organism, for the treatment of Alzheimer’s disease (AD), which is in the clinical testing stage. Preclinical studies have also demonstrated...
Joshua Silverman
Independent Chairman of the Board
Alan Tuchman M.D.
Chief Executive Officer, Director
Daniel Alkon M.D.
President, Chief Scientific Officer, Director
Robert Weinstein
Chief Financial Officer, Executive Vice President, Treasurer, Secretary
Address
1185 AVENUE OF THE AMERICAS, 3RD FLOOR
New York, NY
10036
United States

Top Peers

SYMBOLLASTCHG%CHG
NEXI
Neximmune Inc
3.40-0.06-1.88%
BPTH
Bio Path Holdings Inc
2.34+0.10+4.46%
PALI
Palisade Bio Inc
6.46+0.08+1.25%
PCSA
Processa Pharmaceuticals Inc
2.00-0.02-0.99%
ARTH